MONTE ROSA THERAPEUTICS INC (GLUE) Fundamental Analysis & Valuation

NASDAQ:GLUE • US61225M1027

Current stock price

17.09 USD
-0.08 (-0.47%)
At close:
17.09 USD
0 (0%)
After Hours:

This GLUE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. GLUE Profitability Analysis

1.1 Basic Checks

  • GLUE had negative earnings in the past year.
  • GLUE had a positive operating cash flow in the past year.
  • In the past 5 years GLUE always reported negative net income.
  • In the past 5 years GLUE reported 4 times negative operating cash flow.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 4.56%, GLUE belongs to the best of the industry, outperforming 90.52% of the companies in the same industry.
  • With an excellent Return On Equity value of 8.52%, GLUE belongs to the best of the industry, outperforming 92.07% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 1.69%, GLUE belongs to the top of the industry, outperforming 88.39% of the companies in the same industry.
Industry RankSector Rank
ROA 4.56%
ROE 8.52%
ROIC 1.69%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • GLUE's Profit Margin of 11.54% is amongst the best of the industry. GLUE outperforms 91.49% of its industry peers.
  • The Operating Margin of GLUE (4.69%) is better than 88.59% of its industry peers.
Industry RankSector Rank
OM 4.69%
PM (TTM) 11.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GLUE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GLUE is destroying value.
  • GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.53 indicates that GLUE is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of GLUE (3.53) is better than 69.25% of its industry peers.
  • There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.53
ROIC/WACC0.18
WACC9.21%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • GLUE has a Current Ratio of 6.54. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
  • GLUE has a Current ratio of 6.54. This is in the better half of the industry: GLUE outperforms 64.41% of its industry peers.
  • A Quick Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
  • GLUE has a better Quick ratio (6.54) than 64.99% of its industry peers.
Industry RankSector Rank
Current Ratio 6.54
Quick Ratio 6.54
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GLUE Growth Analysis

3.1 Past

  • GLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.94%, which is quite impressive.
EPS 1Y (TTM)52.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-343.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.41%

3.2 Future

  • Based on estimates for the next years, GLUE will show a very negative growth in Earnings Per Share. The EPS will decrease by -18.07% on average per year.
  • Based on estimates for the next years, GLUE will show a small growth in Revenue. The Revenue will grow by 7.96% on average per year.
EPS Next Y-170.8%
EPS Next 2Y-83.18%
EPS Next 3Y-48.01%
EPS Next 5Y-18.07%
Revenue Next Year-60.31%
Revenue Next 2Y-32.88%
Revenue Next 3Y-44.84%
Revenue Next 5Y7.96%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

2

4. GLUE Valuation Analysis

4.1 Price/Earnings Ratio

  • GLUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GLUE is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, GLUE is valued cheaper than 97.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.59
EV/EBITDA 39.91
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • GLUE's earnings are expected to decrease with -48.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.18%
EPS Next 3Y-48.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GLUE Dividend Analysis

5.1 Amount

  • No dividends for GLUE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GLUE Fundamentals: All Metrics, Ratios and Statistics

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (4/2/2026, 8:00:01 PM)

After market: 17.09 0 (0%)

17.09

-0.08 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)05-06
Inst Owners95.14%
Inst Owner Change6.61%
Ins Owners0.97%
Ins Owner Change1.38%
Market Cap1.25B
Revenue(TTM)N/A
Net Income(TTM)20.95M
Analysts85.33
Price Target30.77 (80.05%)
Short Float %15.18%
Short Ratio9.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.01%
PT rev (3m)41.25%
EPS NQ rev (1m)-2.07%
EPS NQ rev (3m)-6.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.86
P/FCF 8.59
P/OCF 8.36
P/B 5.07
P/tB 5.07
EV/EBITDA 39.91
EPS(TTM)-0.48
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)1.99
FCFY11.64%
OCF(TTM)2.05
OCFY11.97%
SpS2.49
BVpS3.37
TBVpS3.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 4.56%
ROE 8.52%
ROCE 2.14%
ROIC 1.69%
ROICexc 94.17%
ROICexgc 94.17%
OM 4.69%
PM (TTM) 11.54%
GM N/A
FCFM 79.89%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 49.42%
Cap/Sales 2.27%
Interest Coverage 250
Cash Conversion 885.62%
Profit Quality 692.36%
Current Ratio 6.54
Quick Ratio 6.54
Altman-Z 3.53
F-Score8
WACC9.21%
ROIC/WACC0.18
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-343.48%
EPS Next Y-170.8%
EPS Next 2Y-83.18%
EPS Next 3Y-48.01%
EPS Next 5Y-18.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.41%
Revenue Next Year-60.31%
Revenue Next 2Y-32.88%
Revenue Next 3Y-44.84%
Revenue Next 5Y7.96%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A

MONTE ROSA THERAPEUTICS INC / GLUE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to GLUE.


What is the valuation status of MONTE ROSA THERAPEUTICS INC (GLUE) stock?

ChartMill assigns a valuation rating of 2 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Overvalued.


How profitable is MONTE ROSA THERAPEUTICS INC (GLUE) stock?

MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.


Can you provide the financial health for GLUE stock?

The financial health rating of MONTE ROSA THERAPEUTICS INC (GLUE) is 8 / 10.


What is the earnings growth outlook for MONTE ROSA THERAPEUTICS INC?

The Earnings per Share (EPS) of MONTE ROSA THERAPEUTICS INC (GLUE) is expected to decline by -170.8% in the next year.